![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The collaboration aims to assist MIRA in the research and development of Ketamir-2 (ketamir analog), which aids individuals struggling with major depressive disorder with suicidal ideation.
Lead Product(s): Ketamine Analog
Therapeutic Area: Psychiatry/Psychology Product Name: Ketamir-2
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Mira Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 08, 2024